Source comparison
Comparison Table: Melanotan-2 vs Alternative Photoprotection Methods
This table compares MT-2 against standard photoprotection approaches based on peer-reviewed clinical trial data through 2026. Melanotan-2 (0.16 mg/kg protocol) 200–300% 10–14 days 55–89% (controlled trials) Not FDA-approved; banned in EU/Australia Strongest ph
This comparison does not assign a generated winner or score.
- This table compares MT-2 against standard photoprotection approaches based on peer-reviewed clinical trial data through 2026.
- Melanotan-2 (0.16 mg/kg protocol)
- 200–300%
- 10–14 days
- 55–89% (controlled trials)
- Not FDA-approved; banned in EU/Australia
- Strongest photoprotection effect ever measured in UV-free context, but side effect profile and lack of regulatory approval make clinical use untenable. Research-grade compound only.
- Afamelanotide implant (Scenesse)
- 180–220%
- 14–21 days
- 15–25%
- FDA-approved for erythropoietic protoporphyria
- Approved selective MC1R agonist with superior safety profile. Implant format and narrow indication (EPP) limit cosmetic use. Costs $8,000–$12,000 per implant in clinical settings.
- SPF 50+ broad-spectrum sunscreen
- ~95% UVB block
- Immediate (topical)
- <5% (contact dermatitis)
- FDA-approved as OTC drug
- No systemic photoprotection. Effectiveness depends entirely on proper application (2 mg/cm² every 2 hours). Does not increase baseline MED; only blocks incident UV.
- Beta-carotene supplementation (25 mg daily)
- 10–20%
- 8–12 weeks
- <5% (skin yellowing)
- OTC supplement; GRAS status
- Weak photoprotective effect through carotenoid deposition. Requires months of consistent use. Not recommended by dermatology guidelines due to minimal efficacy.
- Polypodium leucotomos extract (480 mg)
- 4–6 weeks
- <5%
- OTC supplement
- Modest antioxidant-mediated photoprotection. No melanogenesis. Evidence limited to shorter-term UVB exposure models.